Why the study?
Does endothelin receptor stimulation alter coronary artery diameter and flow in anesthetized dogs?
Does endothelin receptor stimulation alter coronary artery diameter and flow in anesthetized dogs?
Answers are grounded in this paper and cite their sources.
Conduit coronary constriction and proarrhythmic activity of ET-1 in dogs are mediated predominantly by ETA receptors, whereas resistance vessel constriction is partially generated by ETB receptors and opposed by nitric oxide release.
Summary: The effects of endothelin-1 (ET-1), an ETA/ETB-receptor agonist, and IRL 1620, a potent and selective ETB-receptor agonist, were assessed on left circumflex coronary artery diameter (sonomicrometry) and flow (electromagnetic flow probe) in pentobarbital-anesthetized dogs. Intracoronary (i.c.) bolus injections of ET-1 (80 pmol/dose) caused large, sustained coronary diameter decreases (281 ± 39 μm) and transient flow increases (5.6 ± 2.6 ml/min), followed by transient (10.0 ± 1.9 ml/min) and then sustained flow reductions (6.6 ± 2.5 ml/min) before terminating in ventricular fibrillation after two to five doses (max Δs; n = 4 dogs). IRL 1620 boluses (5-2,000 pmol/dose i.c.; max Δs; n = 3) also dose-dependently and transiently increased (16.8 ± 1.4 ml/min; 200 pmol), then transiently decreased (12.8 ± 1.5 ml/min; 1,600 pmol) flow but had minimal effects on diameter (Δ = -23 ± 4 μm; 2,000 pmol). Doses of IRL 1620 beyond 400 pmol were accompanied by a slowly responding, sustained decrease in baseline flow (-9.2 ± 2.7 ml/min) and baseline diameter (232 ± 150 μm). In a separate group of dogs (n = 5), IRL 1620 (400 pmol i.c.) was evaluated before and after sequential inhibition of cyclooxygenase (indomethacin; 10 mg/kg i.v.) and then nitric oxide synthase (Nw-nitro-L-arginine methyl ester, L-NAME; 50 mg/kg i.v.). Indomethacin alone did not affect the flow increase to IRL 1620 (11.0 ± 2.0 versus 11.8 ± 1.8 ml/min) but blunted the flow decrease by 30 ± 6% (10.6 ± 1.4 versus 7.1 ± 0.7 ml/min). Combined indomethacin plus L-NAME reduced the IRL 1620-mediated flow increment by 66 ± 8% (3.4 ± 0.8 ml/min), returned the flow decrement to control (11.0 ± 1.5 ml/min), and markedly prolonged the time for the flow decrement to recover by 80% (172 ± 27 versus 406 ± 50 s), but did not unmask a transient conduit coronary diameter decrease (-26 ± 13 versus -21 ± 10 μm). IRL 1620 was rarely arrhythmogenic and never induced ventricular fibrillation. Our results suggest that conduit coronary constriction and proarrhythmic activity of ET-1 in dogs are mediated predominantly by ETA receptors, whereas resistance vessel constriction may at least in part be generated by ETB receptors. ETB vasoconstriction is opposed by an ETB-mediated release of nitric oxide.
No takes yet. Share an insight, caveat, or question.
Rigel et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: